Ventyx biosciences reports second quarter 2024 financial results and highlights recent corporate progress

A phase 2 obesity and cardiometabolic trial of vtx3232 and a phase 2a trial of vtx3232 in patients with parkinson's disease are both expected to initiate in h2 2024

VTYX Ratings Summary

VTYX Quant Ranking